India to Nepal: Adalimumab Export Trade Route

To import Adalimumab formulations into Nepal, the following approvals and registrations are mandatory:

1. Company Registration: Foreign pharmaceutical manufacturers must register their company with the DDA. This involves submitting a valid Good Manufacturing Practice (GMP) certificate issued by a competent authority, demonstrating compliance with WHO-GMP standards. (dda.gov.np)

The DDA conducts a thorough evaluation, including laboratory testing, before granting registration. (dda.gov.np)

3. Import License: After product registration, importers must obtain an import recommendation letter from the DDA. This letter is necessary to secure an import license from the Department of Customs. (dda.gov.np)

Timelines and Fees: The approval timelines can vary, but the DDA aims to process company and product registrations within a reasonable period. Specific timelines and registration fees are detailed in the DDA's official guidelines. (dda.gov.np)

GMP Inspection Requirements: The DDA may conduct inspections of foreign manufacturing facilities to verify compliance with GMP standards. Indian manufacturers exporting to Nepal should ensure their facilities are prepared for such inspections. (dda.gov.np)

Indian pharmaceutical exporters supplying Adalimumab formulations to Nepal must adhere to the following quality and GMP standards:

1. GMP Certification: Manufacturers must possess a valid WHO-GMP certificate issued by the competent authority in India, such as the Central Drugs Standard Control Organization (CDSCO). This certification confirms that the manufacturing practices meet international quality standards. (dda.gov.np)

2. Approved Facilities: Only manufacturing facilities that have been registered and approved by the DDA are authorized to export pharmaceutical products to Nepal. The DDA maintains a list of such approved facilities. (dda.gov.np)

3. Regulatory Actions: The DDA conducts regular inspections and quality assessments of imported pharmaceutical products. Any non-compliance with GMP standards or quality issues can lead to regulatory actions, including suspension or cancellation of product registrations. (dda.gov.np)

In the past 18 months, several regulatory developments have impacted Indian pharmaceutical exports to Nepal:

1. Amendments to the Drug Act: In 2024, the Drug Act 2035 was amended to introduce stricter penalties for non-compliance with GMP standards and to streamline the registration process for foreign manufacturers.

2. Implementation of the National GMP Code 2072: Revised in 2025, this code aligns Nepal's GMP standards with international practices, affecting all pharmaceutical imports.

3. Introduction of the Essential Drug List (EDL) 2025: The updated EDL includes Adalimumab formulations, emphasizing the need for stringent quality control and compliance for these products.

These developments underscore Nepal's commitment to ensuring the quality and safety of imported pharmaceutical products, necessitating strict adherence to regulatory requirements by Indian exporters.

As of 2024, the Nepalese market for Adalimumab formulations is in its nascent stages, with limited data available on market size and demand. The primary drivers for Adalimumab demand include the prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. In 2024, Nepal's healthcare expenditure was approximately 6% of its GDP, reflecting a commitment to improving healthcare services. The aging population, with a median age of 25 years in 2024, is expected to contribute to increased demand for treatments addressing chronic conditions. Nepal's universal health coverage initiatives aim to enhance access to essential medicines, potentially influencing the demand for biologic therapies like Adalimumab. Currently, Nepal relies heavily on imports for Adalimumab formulations, with minimal domestic manufacturing capabilities for such specialized biologics.

Nepal imposes a 0% import duty on pharmaceutical products under HS code 30021500, which includes Adalimumab formulations. However, a 13% Value Added Tax (VAT) is applied to these imports. The trade agreement between India and Nepal facilitates the import of pharmaceutical products, including Adalimumab formulations, without additional tariffs. There are no anti-dumping duties imposed on these imports.

India is a significant supplier of Adalimumab formulations to Nepal, accounting for approximately 9% of Nepal's total imports under HS code 30021500. Other major suppliers include the United States and Germany, contributing 41% and 21% respectively to Nepal's imports in this category. India's pricing for Adalimumab formulations is generally more competitive compared to European manufacturers, offering cost advantages due to lower production costs and proximity. This pricing strategy enhances India's position in the Nepalese market for Adalimumab formulations.

India has solidified its position as a global leader in the production of generic pharmaceuticals, including complex biologics like Adalimumab formulations. As of November 2024, India registered 376 pharmaceutical manufacturing facilities with the U.S. Food and Drug Administration (FDA), comprising 200 active pharmaceutical ingredient (API) facilities and 134 finished dosage form (FDF) facilities. This extensive infrastructure underscores India's capacity to produce high-quality finished pharmaceutical formulations.

The country's cost-effective manufacturing processes, driven by economies of scale and a skilled workforce, enable the production of Adalimumab formulations at competitive prices. Additionally, India's adherence to stringent international quality standards is evident, with numerous facilities holding certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and approvals from the FDA. This combination of affordability and quality makes India a preferred source for Adalimumab formulations globally.

When comparing Adalimumab formulation exports from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: In China, the median weighted average price (WAP) for Adalimumab biosimilars was 82% of the reference drug's price as of November 2024. While specific pricing data for India and the EU is not provided, India's cost-effective manufacturing processes often result in more affordable formulations compared to the EU's branded generics.

• Quality Perception: India's pharmaceutical industry is recognized for its adherence to international quality standards, with numerous facilities holding WHO-GMP certifications and FDA approvals. China has been expanding its FDA-registered generic facilities, reaching 169 by November 2024, indicating improvements in quality standards. The EU maintains a strong reputation for high-quality pharmaceutical products.

• Regulatory Acceptance in Nepal: India's pharmaceutical products are widely accepted in Nepal, facilitated by geographical proximity and established trade relations. Chinese and EU products may face more stringent regulatory scrutiny or longer approval processes in Nepal.

• Supply Reliability Track Record: India's extensive manufacturing capacity and experience in exporting pharmaceuticals contribute to a reliable supply chain for Adalimumab formulations. China's growing infrastructure indicates potential for reliable supply, while the EU's stringent regulations ensure consistent quality but may result in higher costs.

India's pharmaceutical industry boasts significant manufacturing capacity for finished dosage forms, including Adalimumab formulations. The country's facilities are equipped with advanced packaging and cold chain capabilities essential for biologics. As of November 2024, India maintained 134 FDA-registered FDF facilities, reflecting substantial production capacity.

The regulatory compliance track record of Indian manufacturers is strong, with many facilities holding WHO-GMP certifications and FDA approvals. While specific data on recent supply disruptions is not provided, India's established infrastructure and experience in pharmaceutical exports suggest a reliable supply chain for Adalimumab formulations.

For Nepalese buyers sourcing Adalimumab formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure consistent product availability.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, such as letters of credit or advance payments, to build trust and ensure timely deliveries.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and quality assessments, to ensure suppliers meet international standards and regulatory requirements.

• Regulatory Compliance: Verify that the selected suppliers have the necessary certifications (e.g., WHO-GMP, FDA approvals) and that their products are registered with Nepal's regulatory authorities to facilitate smooth importation and distribution.

By adhering to these guidelines, Nepalese pharmaceutical companies can establish robust supplier qualification processes, ensuring the procurement of high-quality Adalimumab formulations from reputable Indian manufacturers.